Does the media refer more to ARCT or COYA?

In the previous week, Arcturus Therapeutics had 3 more articles in the media than Coya Therapeutics. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 2 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.24 beat Arcturus Therapeutics' score of 0.23 indicating that Coya Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PRTA or COYA more profitable?

Prothena has a net margin of -80.68% compared to Coya Therapeutics' net margin of -270.22%. Prothena's return on equity of -16.45% beat Coya Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Prothena -80.68% -16.45% -14.51% Coya Therapeutics -270.22% -52.05% -46.34%

Does the media favor PRTA or COYA?

In the previous week, Prothena had 3 more articles in the media than Coya Therapeutics. MarketBeat recorded 5 mentions for Prothena and 2 mentions for Coya Therapeutics. Prothena's average media sentiment score of 1.34 beat Coya Therapeutics' score of 0.24 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, AGMB or COYA?

Coya Therapeutics has higher revenue and earnings than AgomAb Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A Coya Therapeutics $7.95M 15.64 -$21.23M -$1.07 N/A

Does the media refer more to AGMB or COYA?

In the previous week, AgomAb Therapeutics had 1 more articles in the media than Coya Therapeutics. MarketBeat recorded 3 mentions for AgomAb Therapeutics and 2 mentions for Coya Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.51 beat Coya Therapeutics' score of 0.24 indicating that AgomAb Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Coya Therapeutics (COYA) Competitors

$5.30 +0.35 (+7.07%)

Closing price 04:00 PM Eastern

Extended Trading

$5.39 +0.09 (+1.75%)

As of 04:19 PM Eastern

Compare

COYA vs. ARCT, PRTA, KYTX, AGMB, and CABA

Should you buy Coya Therapeutics stock or one of its competitors? Coya Therapeutics's main competitors and comparable companies include Arcturus Therapeutics (ARCT), Prothena (PRTA), Kyverna Therapeutics (KYTX), AgomAb Therapeutics (AGMB), and Cabaletta Bio (CABA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Coya Therapeutics compare to Arcturus Therapeutics?

Arcturus Therapeutics (NASDAQ:ARCT) and Coya Therapeutics (NASDAQ:COYA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Arcturus Therapeutics presently has a consensus price target of $23.00, indicating a potential upside of 59.94%. Coya Therapeutics has a consensus price target of $15.33, indicating a potential upside of 189.31%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Coya Therapeutics is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 6.1% of Coya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Coya Therapeutics has lower revenue, but higher earnings than Arcturus Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$18.72M	21.83	-$65.78M	-$3.31	N/A
Coya Therapeutics	$7.95M	15.64	-$21.23M	-$1.07	N/A

Arcturus Therapeutics has a beta of 2.48, indicating that its stock price is 148% more volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

In the previous week, Arcturus Therapeutics had 3 more articles in the media than Coya Therapeutics. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 2 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.24 beat Arcturus Therapeutics' score of 0.23 indicating that Coya Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Coya Therapeutics has a net margin of -270.22% compared to Arcturus Therapeutics' net margin of -317.62%. Arcturus Therapeutics' return on equity of -46.54% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%
Coya Therapeutics	-270.22%	-52.05%	-46.34%

Summary

Arcturus Therapeutics beats Coya Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Coya Therapeutics compare to Prothena?

Prothena (NASDAQ:PRTA) and Coya Therapeutics (NASDAQ:COYA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

97.1% of Prothena shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 10.4% of Prothena shares are owned by company insiders. Comparatively, 6.1% of Coya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Prothena has a beta of -0.33, meaning that its stock price is 133% less volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

In the previous week, Prothena had 3 more articles in the media than Coya Therapeutics. MarketBeat recorded 5 mentions for Prothena and 2 mentions for Coya Therapeutics. Prothena's average media sentiment score of 1.34 beat Coya Therapeutics' score of 0.24 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prothena currently has a consensus target price of $24.57, indicating a potential upside of 173.32%. Coya Therapeutics has a consensus target price of $15.33, indicating a potential upside of 189.31%. Given Coya Therapeutics' higher possible upside, analysts clearly believe Coya Therapeutics is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Coya Therapeutics has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$54.53M	8.63	-$244.09M	-$0.84	N/A
Coya Therapeutics	$7.95M	15.64	-$21.23M	-$1.07	N/A

Prothena has a net margin of -80.68% compared to Coya Therapeutics' net margin of -270.22%. Prothena's return on equity of -16.45% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
Coya Therapeutics	-270.22%	-52.05%	-46.34%

Summary

Prothena beats Coya Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Coya Therapeutics compare to Kyverna Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

Coya Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market.

Coya Therapeutics has higher revenue and earnings than Kyverna Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	15.64	-$21.23M	-$1.07	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A

Kyverna Therapeutics has a net margin of 0.00% compared to Coya Therapeutics' net margin of -270.22%. Coya Therapeutics' return on equity of -52.05% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
Kyverna Therapeutics	N/A	-81.92%	-63.74%

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Coya Therapeutics currently has a consensus price target of $15.33, indicating a potential upside of 189.31%. Kyverna Therapeutics has a consensus price target of $30.00, indicating a potential upside of 299.47%. Given Kyverna Therapeutics' higher probable upside, analysts plainly believe Kyverna Therapeutics is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Coya Therapeutics had 2 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 2 mentions for Coya Therapeutics and 0 mentions for Kyverna Therapeutics. Coya Therapeutics' average media sentiment score of 0.24 beat Kyverna Therapeutics' score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Coya Therapeutics	Neutral
Kyverna Therapeutics	Neutral

Summary

Coya Therapeutics beats Kyverna Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Coya Therapeutics compare to AgomAb Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and Coya Therapeutics (NASDAQ:COYA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

In the previous week, AgomAb Therapeutics had 1 more articles in the media than Coya Therapeutics. MarketBeat recorded 3 mentions for AgomAb Therapeutics and 2 mentions for Coya Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.51 beat Coya Therapeutics' score of 0.24 indicating that AgomAb Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AgomAb Therapeutics has a net margin of 0.00% compared to Coya Therapeutics' net margin of -270.22%. AgomAb Therapeutics' return on equity of 0.00% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Coya Therapeutics	-270.22%	-52.05%	-46.34%

AgomAb Therapeutics currently has a consensus target price of $37.50, indicating a potential upside of 226.37%. Coya Therapeutics has a consensus target price of $15.33, indicating a potential upside of 189.31%. Given AgomAb Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe AgomAb Therapeutics is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Coya Therapeutics has higher revenue and earnings than AgomAb Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
Coya Therapeutics	$7.95M	15.64	-$21.23M	-$1.07	N/A

39.8% of Coya Therapeutics shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

AgomAb Therapeutics beats Coya Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Coya Therapeutics compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and Coya Therapeutics (NASDAQ:COYA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

Cabaletta Bio has a net margin of 0.00% compared to Coya Therapeutics' net margin of -270.22%. Coya Therapeutics' return on equity of -52.05% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-128.27%	-95.47%
Coya Therapeutics	-270.22%	-52.05%	-46.34%

Coya Therapeutics has higher revenue and earnings than Cabaletta Bio. Coya Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A
Coya Therapeutics	$7.95M	15.64	-$21.23M	-$1.07	N/A

39.8% of Coya Therapeutics shares are owned by institutional investors. 6.4% of Cabaletta Bio shares are owned by company insiders. Comparatively, 6.1% of Coya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cabaletta Bio has a beta of 3.27, suggesting that its stock price is 227% more volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Cabaletta Bio presently has a consensus price target of $15.33, indicating a potential upside of 513.33%. Coya Therapeutics has a consensus price target of $15.33, indicating a potential upside of 189.31%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Coya Therapeutics had 2 more articles in the media than Cabaletta Bio. MarketBeat recorded 2 mentions for Coya Therapeutics and 0 mentions for Cabaletta Bio. Coya Therapeutics' average media sentiment score of 0.24 beat Cabaletta Bio's score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cabaletta Bio	Neutral
Coya Therapeutics	Neutral

Summary

Coya Therapeutics beats Cabaletta Bio on 9 of the 16 factors compared between the two stocks.

Get Coya Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COYA vs. The Competition

Export

Metric	Coya Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$124.34M	$3.96B	$7.29B	$13.28B
Dividend Yield	N/A	3.64%	2.53%	12.80%
P/E Ratio	-4.95	14.51	275.15	25.85
Price / Sales	15.64	1,368.69	683.23	115.70
Price / Cash	N/A	41.62	28.04	34.72
Price / Book	2.57	15.86	10.73	6.45
Net Income	-$21.23M	-$22.82M	$3.49B	$358.26M
7 Day Performance	13.98%	1.99%	2.31%	2.34%
1 Month Performance	8.83%	-3.40%	-1.74%	-2.48%
1 Year Performance	-3.11%	37.14%	17.90%	6.41%

Coya Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COYA Coya Therapeutics	2.2696 of 5 stars	$5.30 +7.1%	$15.33 +189.3%	-10.0%	$124.34M	$7.95M	N/A	8
ARCT Arcturus Therapeutics	2.9445 of 5 stars	$16.19 -4.4%	$23.00 +42.1%	-28.2%	$459.84M	$82.03M	N/A	111
PRTA Prothena	3.4411 of 5 stars	$8.46 -0.1%	$24.57 +190.6%	+5.5%	$442.62M	$9.68M	N/A	67	News Coverage Positive News Insider Trade
KYTX Kyverna Therapeutics	1.4702 of 5 stars	$7.10 +0.8%	$30.00 +322.8%	+22.8%	$438.78M	N/A	N/A	149
AGMB AgomAb Therapeutics	3.6993 of 5 stars	$12.06 -0.2%	$37.50 +211.1%	N/A	$436.84M	N/A	N/A	62	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COYA) was last updated on 9/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coya Therapeutics (COYA) Competitors

COYA vs. ARCT, PRTA, KYTX, AGMB, and CABA

How does Coya Therapeutics compare to Arcturus Therapeutics?

Summary

How does Coya Therapeutics compare to Prothena?

Summary

How does Coya Therapeutics compare to Kyverna Therapeutics?

Summary

How does Coya Therapeutics compare to AgomAb Therapeutics?

Summary

How does Coya Therapeutics compare to Cabaletta Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA vs. The Competition

Coya Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coya Therapeutics (COYA) Competitors

COYA vs. ARCT, PRTA, KYTX, AGMB, and CABA

How does Coya Therapeutics compare to Arcturus Therapeutics?

Do analysts rate ARCT or COYA?

Do insiders & institutionals have more ownership in ARCT or COYA?

Which has preferable valuation & earnings, ARCT or COYA?

Which has more volatility & risk, ARCT or COYA?

Does the media refer more to ARCT or COYA?

Is ARCT or COYA more profitable?

Summary

How does Coya Therapeutics compare to Prothena?

Do insiders & institutionals believe in PRTA or COYA?

Which has more risk & volatility, PRTA or COYA?

Does the media favor PRTA or COYA?

Do analysts rate PRTA or COYA?

Which has stronger earnings and valuation, PRTA or COYA?

Is PRTA or COYA more profitable?

Summary

How does Coya Therapeutics compare to Kyverna Therapeutics?

Which has more risk & volatility, COYA or KYTX?

Which has higher valuation & earnings, COYA or KYTX?

Is COYA or KYTX more profitable?

Do institutionals and insiders hold more shares of COYA or KYTX?

Do analysts recommend COYA or KYTX?

Does the media favor COYA or KYTX?

Summary

How does Coya Therapeutics compare to AgomAb Therapeutics?

Does the media refer more to AGMB or COYA?

Is AGMB or COYA more profitable?

Do analysts recommend AGMB or COYA?

Which has stronger valuation and earnings, AGMB or COYA?

Do insiders and institutionals believe in AGMB or COYA?

Summary

How does Coya Therapeutics compare to Cabaletta Bio?

Is CABA or COYA more profitable?

Which has better earnings and valuation, CABA or COYA?

Do insiders & institutionals believe in CABA or COYA?

Which has more volatility & risk, CABA or COYA?

Do analysts rate CABA or COYA?

Does the media refer more to CABA or COYA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA vs. The Competition

Coya Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools